文献速递妇科肿瘤

BRCA1/2突变复发性上皮性卵巢癌患者在奥拉帕利对比安慰剂维持治疗进展后后续化疗的疗效:SOLO2/ENGOT Ov-21试验的事后分析

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
PubMed 文献 · Ann Oncol · 2022-06-27

该研究为SOLO2试验的事后假设生成分析,纳入147例RECIST进展后接受首个后续化疗的患者,其中安慰剂组69例、奥拉帕利组78例。全组中位至第二进展时间(TTSP)安慰剂组12.1个月 vs 奥拉帕利组6.9个月(HR 2.17,95%CI 1.47-3.19);铂类化疗亚组(n=96)为14.3 vs 7.0个月(HR 2.89,95%CI 1.73-4.82),非铂类亚组(n=51)为8.3 vs 6.0个月(HR 1.58,95%CI 0.86-2.90)。

要点

  • 全组147例中,安慰剂组后续化疗后中位TTSP 12.1个月,奥拉帕利组6.9个月(HR 2.17,95%CI 1.47-3.19)。
  • 铂类化疗亚组(n=96)中位TTSP安慰剂组14.3个月 vs 奥拉帕利组7.0个月(HR 2.89,95%CI 1.73-4.82)。
  • 非铂类化疗亚组(n=51)中位TTSP两组分别为8.3个月与6.0个月(HR 1.58,95%CI 0.86-2.90)。

核心结论

  • 在复发性背景下,BRCA1/2突变铂敏感复发性卵巢癌患者从奥拉帕利维持治疗进展后,后续含铂化疗的疗效似乎较未接受过PARP抑制剂者降低。
  • PARP抑制剂后复发患者的最佳策略仍是正在研究中的领域。

研究设计与样本

  • SOLO2试验(ENGOT Ov-21;NCT01874353)的事后假设生成分析。
  • 研究人群为147例在RECIST疾病进展后接受化疗作为首个后续治疗的患者,其中69例(47%)原随机分配至安慰剂组,78例(53%)分配至奥拉帕利组。

主要发现

  • 在147例接受化疗的患者中,中位至第二进展时间(TTSP)安慰剂组为12.1个月 vs 奥拉帕利组6.9个月(HR 2.17,95%CI 1.47-3.19)。
  • 调整RECIST进展时预后因素的多变量分析结果相似(HR 2.13,95%CI 1.41-3.22)。
  • 接受铂类化疗的患者(n=96)中,中位TTSP安慰剂组14.3个月 vs 奥拉帕利组7.0个月(HR 2.89,95%CI 1.73-4.82)。
  • 接受非铂类化疗的患者(n=51)中,中位TTSP安慰剂组8.3个月 vs 奥拉帕利组6.0个月(HR 1.58,95%CI 0.86-2.90)。
  • 安慰剂组69例中27例接受非铂类、42例接受铂类化疗;奥拉帕利组78例中24例接受非铂类、54例接受铂类化疗。

关键数值与推荐

  • 全组147例中位TTSP:安慰剂组12.1个月 vs 奥拉帕利组6.9个月(HR 2.17,95%CI 1.47-3.19)。
  • 铂类亚组(n=96)中位TTSP:安慰剂组14.3个月 vs 奥拉帕利组7.0个月(HR 2.89,95%CI 1.73-4.82)。
  • 非铂类亚组(n=51)中位TTSP:安慰剂组8.3个月 vs 奥拉帕利组6.0个月(HR 1.58,95%CI 0.86-2.90)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the SOLO2 trial (ENGOT Ov-21; NCT01874353), maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and BRCA mutation significantly improved progression-free survival (PFS) and prolonged overall survival (OS). Following disease progression on olaparib, efficacy of subsequent chemotherapy remains unknown. PATIENTS AND METHODS: We conducted a post-hoc hypothesis-generating analysis of SOLO2 data to determine the efficacy of different chemotherapy regimens following RECIST disease progression in patients who received olaparib or placebo. We evaluated time to second progression (TTSP) calculated from the date of RECIST progression to the next progression/death. RESULTS: The study population comprised 147 patients who received chemotherapy as their first subsequent treatment after RECIST progression. Of these, 69 (47%) and 78 (53%) were originally randomized to placebo and olaparib arms, respectively. In the placebo-treated cohort, 27/69 and 42/69 received non-platinum and platinum-based chemotherapy, respectively, compared with 24/78 and 54/78, respectively, in the olaparib-treated cohort. Among patients treated with chemotherapy (N = 147), TTSP was significantly longer in the placebo than in the olaparib arm: 12.1 versus 6.9 months [hazard ratio (HR) 2.17, 95% confidence interval (CI) 1.47-3.19]. Similar result was obtained on multivariable analysis adjusting for prognostic factors at RECIST progression (HR 2.13, 95% CI 1.41-3.22). Among patients treated with platinum-based chemotherapy (n = 96), TTSP was significantly longer in the placebo arm: 14.3 versus 7.0 months (HR 2.89, 95% CI 1.73-4.82). Conversely, among patients treated with non-platinum-based chemotherapy (n = 51), the TTSP was comparable in the placebo and olaparib arms: 8.3 versus 6.0 months (HR 1.58, 95% CI 0.86-2.90). CONCLUSIONS: Following progression from maintenance olaparib in the recurrent setting, the efficacy of platinum-based subsequent chemotherapy seems to be reduced in BRCA1/2-mutated patients with PSROC compared to patients not previously receiving poly (ADP-ribose) polymerase inhibitors (PARPi). The optimal strategy for patients who relapse after PARPi is an area of ongoing research.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Frenel JS, Kim JW, Aryal N, et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol. 2022. PMID: 35772665. doi:10.1016/j.annonc.2022.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。